Vaccine biotech Emergex name experienced pharma professional Dr Athanasios Papadopoulos as new CMO
Emergex Vaccine Holdings Limited has named Dr Athanasios Papadopoulos as the company’s new Chief Medical Officer (CMO).
The appointment, effective 1 March, will see Dr Papadopoulos report directly to Professor Thomas Rademacher, Emergex’s CEO.
In his new role, Dr Papadopoulos will use his expertise in providing leadership and direction in the development of Emergex’s growing pipeline of vaccines.
Dr Papadopoulos joins Emergex from French firm Sanofi in which he has acted as Associate Vice President, Senior Director and Clinical Franchise Leader of Global Clinical Sciences since 2015.
During his time at Sanofi, Dr Papadopoulos contributed to the development of Dengue fever vaccine Dengvaxia.
Prior to joining Sanofi, the pharma chief worked as Medical Affairs Director and Senior Global Clinical Research Physician as well as Lead Head of CLS and Senior Director of Clinical Development in Novartis, during which period he worked on the development and approval of Meningitis B vaccine, Bexsero.
Storme Moore-Thornicroft co-founder and COO at Emergex commented: “It is a testament to the quality of our science that someone with Athanasios’ experience has chosen to join our executive management team. His knowledge and experience working in senior positions and the successful development and approval of a number of vaccines makes him the perfect candidate to be our new CMO. We look forward to working with him as our programmes progress into and through clinical development.”
Dr Papadopoulos originally trained in Greece as a general practitioner (GP) before specialising as a clinical bio-pathology consultant.
On his appointment as Emergex’s new CMO, Dr Athanasios Papadopoulos commented: “Coming from a larger, multinational corporation I am eager to explore the opportunities that come with working in a competitive, entrepreneurial, high-growth Company. Emergex’s novel technology and pipeline hold the potential to revolutionise infectious disease prevention and treatment and I am keen to be a part of the team as they strive to realise that vision.”